Sepsis-associated respiratory failure

Sepsis-associated respiratory failure is a critical complication in which systemic infection leads to widespread inflammation and impaired lung function. The pathophysiology involves a complex interplay of cytokine release, vascular permeability, and tissue injury, resulting in conditions such as acute respiratory distress syndrome (ARDS). Patients often present with hypoxemia, tachypnea, and respiratory distress that progress rapidly without intervention. Diagnosis relies on clinical suspicion supported by biomarkers of infection, imaging studies, and blood gas analysis. Because sepsis triggers multi-organ dysfunction, respiratory failure is often accompanied by hemodynamic instability and renal or hepatic involvement, complicating patient management.

Treatment of sepsis-associated respiratory failure requires simultaneous infection control and organ support. Early administration of broad-spectrum antibiotics, fluid resuscitation, and hemodynamic stabilization form the foundation of care. Respiratory support often includes mechanical ventilation with lung-protective strategies to minimize ventilator-induced injury. Adjunctive therapies such as prone positioning, neuromuscular blockade, or extracorporeal membrane oxygenation (ECMO) may be considered in severe cases. Long-term outcomes depend on both rapid recognition and the prevention of secondary complications, such as ventilator-associated pneumonia or fibrosis. Advances in critical care research are exploring biomarkers for early detection and novel anti-inflammatory agents to mitigate lung injury. Effective management of sepsis-associated respiratory failure demands coordinated multidisciplinary care to improve survival and long-term respiratory function.